English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduFirst-of-its kind work led by Mount Sinai researcher supports reserving this technique for extreme cases
Tag: Late Breaking Trial
SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe and Effective for Treating Patients Who Have Suffered a Heart Attack
The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.
RNA Inhibitor Is Shown Safe and Effective in Reducing a Wide Range of Cholesterol and Triglyceride Levels in the Blood in Mount Sinai-Led Clinical Trial
A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.
Posterior Wall Ablation Does Not Help Patients With Persistent Atrial Fibrillation
FOR IMMEDIATE RELEASE Contact: Ilana Nikravesh Mount Sinai Press Office 212-241-9200 [email protected] …
Coronary Bioresorbable Scaffolds Nearly as Safe and Effective as Conventional Metal Stents for Heart Disease Patients
First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing percutaneous coronary intervention (PCI).
High-Dose Anticoagulation Can Reduce Intubations and Improve Survival for Hospitalized COVID-19 Patients
High-dose anticoagulation can reduce deaths by 30 percent and intubations by 25 percent in hospitalized COVID-19 patients who are not critically ill when compared to the standard treatment, which is low-dose anticoagulation.
Transcatheter Mitral Valve Repair in Heart Failure Patients Significantly Reduces Hospitalizations and Improves Survival
Breakthrough findings from study led by Mount Sinai researcher could improve outcomes for high-risk patients
New Risk Score Predicts Mortality for Atrial Fibrillation Patients Undergoing Transcatheter Aortic Valve Replacement
Mount Sinai researchers develop new risk stratification tool to optimize patient care and outcomes after TAVR